Dr. Frank L. Douglas is an award-winning industry veteran with three decades of experience in healthcare, pharmaceuticals, and entrepreneurship. He served as Executive Vice President, Chief Scientific Officer and Member of the Board of Management of large Pharmaceutical companies such as Aventis AG, now Sanofi, SA. He recently served as CEO of THEVAX Genetics USA Inc. and Member of the Board of TheVax Genetics Vaccine Co. He is also the co-founder of Douglas Ahmed Consulting (DAC). Some of his past experiences include being President and CEO of the Austen BioInnovation Institute in Akron, Executive Vice President, Chief Scientific Officer and Member of the Board of Management of Aventis AG, Chief Scientific Advisor of Bayer Healthcare, AG, Founder and First Executive Director of the MIT Center for Biomedical Innovation, Professor of the Practice in the Massachusetts Institute of Technology (MIT) Sloan School of Management, MIT Departments of Chemistry, Biomedical Engineering and the Harvard-MIT Division of Health Science and Technology.
Dr. Douglas holds a Ph.D. in physical chemistry and an M.D. from Cornell University. He did his internship and residency in internal medicine at the Johns Hopkins Medical Institute and a fellowship in neuroendocrinology at the National Institutes of Health.
In addition to his impressive career achievements, Dr. Douglas has led clinical trials and presented on healthcare disparities at ROCHE Pharma, UK. He conducted workshops and case study presentations at HBCUs namely at Lehigh University and MIT, the University of Akron, and Weill Cornell Medical School.
Dr. Douglas is the founder and CEO of SAFE HAVEN DIALOGUES LLC, and has also authored two groundbreaking books, entitled “Defining Moments of a Free Man from a Black Stream” and “Until You Walk in My Shoes: A Reframing Methodology to Overcome Systemic Discrimination".
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
View all episodes
By Daniel Lucas /Sal Cosenza
5
77 ratings
Dr. Frank L. Douglas is an award-winning industry veteran with three decades of experience in healthcare, pharmaceuticals, and entrepreneurship. He served as Executive Vice President, Chief Scientific Officer and Member of the Board of Management of large Pharmaceutical companies such as Aventis AG, now Sanofi, SA. He recently served as CEO of THEVAX Genetics USA Inc. and Member of the Board of TheVax Genetics Vaccine Co. He is also the co-founder of Douglas Ahmed Consulting (DAC). Some of his past experiences include being President and CEO of the Austen BioInnovation Institute in Akron, Executive Vice President, Chief Scientific Officer and Member of the Board of Management of Aventis AG, Chief Scientific Advisor of Bayer Healthcare, AG, Founder and First Executive Director of the MIT Center for Biomedical Innovation, Professor of the Practice in the Massachusetts Institute of Technology (MIT) Sloan School of Management, MIT Departments of Chemistry, Biomedical Engineering and the Harvard-MIT Division of Health Science and Technology.
Dr. Douglas holds a Ph.D. in physical chemistry and an M.D. from Cornell University. He did his internship and residency in internal medicine at the Johns Hopkins Medical Institute and a fellowship in neuroendocrinology at the National Institutes of Health.
In addition to his impressive career achievements, Dr. Douglas has led clinical trials and presented on healthcare disparities at ROCHE Pharma, UK. He conducted workshops and case study presentations at HBCUs namely at Lehigh University and MIT, the University of Akron, and Weill Cornell Medical School.
Dr. Douglas is the founder and CEO of SAFE HAVEN DIALOGUES LLC, and has also authored two groundbreaking books, entitled “Defining Moments of a Free Man from a Black Stream” and “Until You Walk in My Shoes: A Reframing Methodology to Overcome Systemic Discrimination".
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
0 Listeners
10 Listeners
2 Listeners
0 Listeners
13 Listeners
10 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
13 Listeners
2 Listeners
6 Listeners
3 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners